In the dynamic landscape of pharmaceuticals, 2024 holds immense promise with the impending launch of groundbreaking drugs, particularly in the realm of Central Nervous System (CNS) diseases.
Among the top ten drug launches anticipated in 2024, two notable contenders stand out for their focus on addressing CNS diseases, offering renewed therapeutic hope for patients worldwide:
Hat Tip to Fierce Pharma – Want to find out the other top 10 drugs anticipated to launch in 2024? Visit original post by Fierce Pharma
As the pharmaceutical landscape evolves, we stand at the forefront, offering specialized in vitro and in vivo electrophysiology services tailored to accelerate drug discovery and development processes.
Our comprehensive suite of services encompasses diverse tissue models, including rodents, animals, and human specimens, as well as cellular and slice preparations, facilitating a nuanced understanding of drug mechanisms of action, safety profiles, and toxicity considerations.
Our brain slice electrophysiology platform provides Electrophysiological assays on brain slice from schizophrenic rodent models.
Our preferred partner Key-Obs, expert in models and behavioural assays of neurological disorders, provides behavioural investigations of Tg or pharmacological schizophrenic rodent models.
Our brain slice electrophysiology platform successfully showed that Tg mice display electrophysiological properties deficits compared to their wild type counterparts. As an expert in electrophysiological studies, we can study your compound’s efficacy on such models.
Our cell electrophysiology platform is expert in characterizing, validating and performing pharmacological testing on all types of human iPSC-derived neurons.
Thanks to commercially available iPSCs derived from AD patient donors, we can help you investigate your compound’s activity on human tissue in a condition approaching very closely the physiological condition.
Our in vivo brain electrophysiology platform, a rodent platform entirely dedicated to innovation in experimental psychopathology, provides behavioral test to assess impairments characteristic of AD:
Our preferred partner KEY-OBS, preclinical CNS CRO specialized in in vivo models of neurological disorders, has developed models simulating closely Alzheimer’s Disease symptoms.
Download our data sheet to learn more about one of our assays evaluating a GPR52 agonist on evoked-responses in prefrontal cortex. The molecule evaluated demonstrated antipsychotic-Like and procognitive effects in rodents, suggesting a potential therapeutic agent for schizophrenia.
Through cutting-edge electrophysiological techniques:
As we anticipate the landmark drug launches of 2024, Neuroservices-Alliance remains steadfast in its commitment to driving innovation and catalyzing transformative advancements in CNS therapeutics.
For inquiries regarding our comprehensive electrophysiology services and tailored solutions for CNS drug development, contact Neuroservices-Alliance today!
